API | seladelpar

seladelpar Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. ^Wikipedia

Chemistry

SMILES: CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(OCC(=O)O)c(C)c2
InChIKey: JWHYSEDOYMYMNM-QGZVFWFLSA-N
Mol. Mass: 444.47
ALogP: 5.05 Partition coefficient
ChEMBL Molecule:
seladelpar

More Chemistry

Pharmacology

Mechanism of Action:
- Peroxisome proliferator-activated receptor delta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

seladelpar

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Cholangitis, Sclerosing (Phase 2)

Liver Cirrhosis (Phase 1)

Liver Cirrhosis, Biliary (Phase 3)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue